How to Build CHD@ZJU

CHD related Articles were retrieved from Pubmed, by entering keywords "coronary heart disease" and constrict the publish date from 2000/1/1 to now (2013/1/23). As a result, totally 115898 articles were found and their abstracts were downloaded for text mining. Since some articles didn't contain abstracts, only 88396 abstracts remained.

The text-mining process to get CHD related genes could be divided in to 5 following steps:

  • 1) Extracting all keywords from abstracts and ignoring those keywords start with numbers. 101402 keywords were extracted.

  • 2) Input these keywords into Gene library in ArrayTrack and find possible related genes. 4674 genes were then found.

  • 3) Put these 4674 genes again into pubmed abstracts to find related aticles. Only genes which offical name or there keyword description (such as prolactin for gene PRL) could be found in the abstract would be remained. As a result, 1247 genes were remained.

  • 4) Manually examined on the 1247 genes to validate it was acutally related to CHD. Some genes would be filtered if it represents other meanings (such as gene CAD, Entrez ID:790, carbamoyl-phosphate synthetase 2, is mostly meant coronary arterial disease in articles). 681 genes were then validated with at least one reference.

  • 5) All genes was compared with 1078 CHD genes in RGD database, and 370 genes were overlapped. These 370 genes were labels as "RGD_Supported" and the other 293 genes were labels as "REFERED". All 663 genes had supported references in CHD@ZJU which were examined by step 4.
  • How To contact Us

    Collaboration Information: Prof. Xiaohui Fan (fanxh@zju.edu.cn)

    Website using assistance : Leihong Wu (11019004@zju.edu.cn)



    Basic Information

    Gene Name: CYP2C19

    Description: "cytochrome P450, family 2, subfamily C, polypeptide 19"

    Entrez Gene ID: 1557

    SwissProt Acc Number: P33261

    RefSeq: NM_000769

    It was supported literatures to be a novel CHD related gene:

    .."Besides CYP2C19*2, the variant allele CYP2C9*3 plays an important role in the response to clopidogrel in patients on dual antiplatelet therapy undergoing coronary stenting."..

    From PMID: 19934796, in Journal Pharmacogenet Genomics. , 2010


    References

    There were 74 potential papers with CYP2C19 and CHD.

    PMIDTitleJournalsDetails
    23886632 Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.Journal of cardiologyMore Details
    23850318 Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial.International journal of cardiologyMore Details
    24072532 Clopidogrel use is associated with an increased prevalence of cerebral microbleeds in a stroke-free population: the Rotterdam study.Journal of the American Heart AssociationMore Details
    24019397 CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.Circulation. Cardiovascular geneticsMore Details
    24080325 "Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects."Archives of cardiovascular diseasesMore Details
    24009042 Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.Thrombosis and haemostasisMore Details
    24262617 Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.JACC. Cardiovascular interventionsMore Details
    23337798 The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease.AtherosclerosisMore Details
    22075408 Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests.International journal of cardiologyMore Details
    23618682 Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.Journal of clinical neuroscience : official journal of the Neurosurgical Society More Details
    23549239 The role of clopidogrel in the management of ischemic heart disease.Current opinion in cardiologyMore Details
    23137413 Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.Journal of thrombosis and haemostasis : JTHMore Details
    23351820 Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.American heart journalMore Details
    23602770 The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.Journal of the American College of CardiologyMore Details
    23830212 Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.Thrombosis researchMore Details
    23001453 Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.European journal of clinical pharmacologyMore Details
    23364775 Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.Thrombosis and haemostasisMore Details
    23570358 "Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease."Expert review of cardiovascular therapyMore Details
    23981380 Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care.BMC cardiovascular disordersMore Details
    22234956 Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.Catheterization and cardiovascular interventions : official journal of theMore Details
    23048056 Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.Circulation. Cardiovascular interventionsMore Details
    22489610 "Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor."Clinical pharmacokineticsMore Details
    22568693 Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.Clinical pharmacokineticsMore Details
    22565143 Long-term antiplatelet therapy: from clinical trials to clinical application.Current opinion in cardiologyMore Details
    21445598 A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent.Heart and vesselsMore Details
    21693476 Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.Heart (British Cardiac Society)More Details
    22071359 Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease.AtherosclerosisMore Details
    22142030 Anti-platelet therapy and managing ulcer risk.Journal of gastroenterology and hepatologyMore Details
    22591668 Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.The American journal of cardiologyMore Details
    22589111 Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis.ElectrophoresisMore Details
    22377481 CYP2C19*2 and prognosis after an acute coronary syndrome: Insights from a Portuguese center.Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa deMore Details
    22427735 Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.Clinical pharmacology : advances and applicationsMore Details
    21806387 Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.PharmacogenomicsMore Details
    21786436 Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease.Yonsei medical journalMore Details
    22028352 "Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis."JAMA : the journal of the American Medical AssociationMore Details
    21215696 Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis."Heart, lung & circulation"More Details
    21706290 Genetic determinants of platelet response to clopidogrel.Journal of thrombosis and thrombolysisMore Details
    21550074 Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients.Metabolism: clinical and experimentalMore Details
    21479337 Genetic variability in response to clopidogrel therapy and its clinical implications.Thrombosis and haemostasisMore Details
    21168310 Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy.Journal of cardiologyMore Details
    21392617 The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.American heart journalMore Details
    20965214 Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond.Pharmacology & therapeuticsMore Details
    21544314 "Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy."Thrombosis and haemostasisMore Details
    21527445 No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.European heart journalMore Details
    21075428 The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.Thrombosis researchMore Details
    21178986 Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.Clinical pharmacology and therapeuticsMore Details
    22203539 "CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis."JAMA : the journal of the American Medical AssociationMore Details
    21862109 Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.Thrombosis researchMore Details
    21819266 Clopidogrel pharmacogenetics: metabolism and drug interactions.Drug metabolism and drug interactionsMore Details
    20826260 Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.American heart journalMore Details
    20460345 Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population.Clinical and applied thrombosis/hemostasis : official journal of theMore Details
    20965456 Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.JACC. Cardiovascular interventionsMore Details
    20435227 Clinical assessment incorporating a personal genome.LancetMore Details
    20230261 Factors associated with clopidogrel nonresponsiveness.Future cardiologyMore Details
    20538118 Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention.The American journal of cardiologyMore Details
    20510210 Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.Journal of the American College of CardiologyMore Details
    20620727 Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.Journal of the American College of CardiologyMore Details
    20421791 Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.Current opinion in cardiologyMore Details
    19934793 "Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation."Pharmacogenetics and genomicsMore Details
    20083681 "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement."CirculationMore Details
    21107514 [Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010].HerzMore Details
    21079055 First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.Circulation. Cardiovascular geneticsMore Details
    20651323 Considerations in patients receiving oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention.American journal of health-system pharmacy : AJHP : official journal of theMore Details
    20877456 Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.PLoS currentsMore Details
    21151850 Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease.Clinical Medicine Insights. CardiologyMore Details
    19891556 Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.PharmacogenomicsMore Details
    19429918 Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.European heart journalMore Details
    19081411 Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.American heart journalMore Details
    19932784 Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.The American journal of cardiologyMore Details
    19726525 Clinical pharmacology of antithrombotic drugs in coronary artery disease.Therapeutic advances in cardiovascular diseaseMore Details
    19193675 Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.European heart journalMore Details
    18781853 CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.PharmacogenomicsMore Details
    19463375 The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.JACC. Cardiovascular interventionsMore Details
    17868191 Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis.Cell biochemistry and functionMore Details

    NOTEs: These result is mostly from TEXT-MINING and there might have mismatches.



    PPI interactions

    There were totally 1 unique genes interacted with CYP2C19. Show PPI network

    Gene nameInteraction typereference PMIDCHD relation
    POR Reconstituted Complex9398194 No


    Involved FDA drugs

    There was no drug associated with CYP2C19